Merck KGaA stock climbed sharply following the companys first-quarter results and an improved full-year profit outlook. Shares rose 8.8% to trade at 122.9 after the Darmstadt-based science and technology group reported quarterly figures that beat expectations and lifted its adjusted EBITDA guidance for fiscal 2026.
Management raised the full-year adjusted EBITDA range to 5.76.1 billion, up from the prior guidance of 5.56.0 billion. The company attributed the upward revision to stronger momentum in its Life Science division and to delayed competition for the multiple sclerosis medicine Mavenclad. The improved outlook followed a quarter in which Merck KGaA saw healthier-than-anticipated demand for its semiconductor offerings within the electronics segment.
On the headline numbers, net profit for the quarter fell 9.4% year-on-year to 669 million, or 2.11 per share. That result exceeded consensus forecasts of 1.99 per share. Net sales dropped 2.8% to 5.13 billion, which also topped estimates of 5.09 billion.
The stronger start to the fiscal year coincides with a recent leadership change at the top of the company. Kai Beckmann, who was promoted earlier this month from his role as head of the electronics division, has begun his tenure as chief executive as the company posts an earnings beat and a guidance upgrade.
Analyst coverage remains favorable. The consensus rating on Merck KGaA stands at Buy based on 15 analysts, 11 of whom recommend a purchase. The average 12-month price target among those analysts is 143.20. UBS is among the brokerages that had maintained a Buy rating ahead of the quarterly report.
Market context also supported the stocks move. Germanys DAX rose 0.7% to 24,126 points in early trading, recovering following losses in the prior session. The pan-European STOXX 600 was up 0.7% as of early Wednesday morning, reversing a drop of more than 1% from Tuesday. The market tone was further buoyed by reports that US President Donald Trumps state visit to China rekindled hopes for easing trade tensions between the United States and China.
Institutional buying added to the favorable backdrop. Amundi S.A. recently increased its stake in Merck KGaA, a move that the market interpreted as growing institutional conviction ahead of the earnings release.
The combination of the quarterly earnings beat, the upgraded full-year EBITDA guidance, positive analyst sentiment, and a recovering German equity market produced a strong set of catalysts for the stock. Merck KGaA led the DAX for the sessions largest gain, pushing toward an intraday high of 123.55 and narrowing the gap to its 52-week high of 131.65.
Impact summary
- Company: Merck KGaA posted a Q1 earnings beat and raised fiscal 2026 adjusted EBITDA guidance to 5.76.1 billion.
- Market reaction: Shares jumped 8.8% to 122.9, leading DAX gains and moving toward a day high of 123.55.
- Drivers: Strength in Life Science, robust semiconductor demand, delayed competition for Mavenclad, and supportive analyst coverage.